BlackRock’s AbbVie ABBV Stock Holding History

BlackRock’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.8B	Sell	150,698,125 -476,418	-0.3%	-$106M	0.57%	22
2025 Q4	$34.5B	Buy	151,174,543 +5,197,454	+4%	+$1.18B	0.58%	19
2025 Q3	$33.8B	Sell	145,977,089 -1,478,975	-1%	-$301M	0.59%	22
2025 Q2	$27.4B	Buy	147,456,064 +1,577,922	+1%	+$293M	0.52%	24
2025 Q1	$30.6B	Buy	145,878,142 +3,842,577	+3%	+$747M	0.64%	21
2024 Q4	$25.2B	Buy	142,035,565 +6,062,998	+4%	+$1.11B	0.51%	25
2024 Q3	$26.9B	Sell	135,972,567 -458,943	-0.3%	-$85.7M	0.56%	23
2024 Q2	$23.4B	Sell	136,431,510 -6,527,594	-5%	-$1.08B	0.53%	23
2024 Q1	$26B	Sell	142,959,104 -223,605	-0.2%	-$38.5M	0.61%	21
2023 Q4	$22.2B	Buy	143,182,709 +5,165,853	+4%	+$753M	0.57%	22
2023 Q3	$20.6B	Sell	138,016,856 -1,144,940	-0.8%	-$168M	0.59%	23
2023 Q2	$18.7B	Buy	139,161,796 +440,286	+0.3%	+$64.6M	0.52%	24
2023 Q1	$22.1B	Buy	138,721,510 +18,752	+0%	+$2.87M	0.65%	21
2022 Q4	$22.4B	Buy	138,702,758 +5,742,609	+4%	+$881M	0.7%	21
2022 Q3	$17.8B	Sell	132,960,149 -1,740,499	-1%	-$250M	0.61%	23
2022 Q2	$20.6B	Buy	134,700,648 +5,069,770	+4%	+$775M	0.66%	19
2022 Q1	$21B	Buy	129,630,878 +1,433,324	+1%	+$208M	0.57%	20
2021 Q4	$17.4B	Buy	128,197,554 +1,358,115	+1%	+$160M	0.44%	31
2021 Q3	$13.7B	Buy	126,839,439 +4,247,445	+3%	+$485M	0.38%	43
2021 Q2	$13.8B	Sell	122,591,994 -4,024,003	-3%	-$453M	0.38%	41
2021 Q1	$13.7B	Buy	126,615,997 +2,192,513	+2%	+$235M	0.4%	38
2020 Q4	$13.3B	Buy	124,423,484 +2,406,847	+2%	+$231M	0.43%	37
2020 Q3	$10.7B	Sell	122,016,637 -1,339,787	-1%	-$126M	0.39%	42
2020 Q2	$12.1B	Buy	123,356,424 +21,974,440	+22%	+$1.93B	0.48%	35
2020 Q1	$7.72B	Buy	101,381,984 +2,788,174	+3%	+$237M	0.38%	46
2019 Q4	$8.73B	Sell	98,593,810 -3,045,226	-3%	-$253M	0.33%	50
2019 Q3	$7.7B	Buy	101,639,036 +3,343,764	+3%	+$229M	0.32%	51
2019 Q2	$7.15B	Buy	98,295,272 +3,100,309	+3%	+$244M	0.31%	56
2019 Q1	$7.67B	Sell	95,194,963 -593,936	-0.6%	-$48.6M	0.34%	49
2018 Q4	$8.83B	Buy	95,788,899 +237,268	+0.2%	+$20.9M	0.45%	35
2018 Q3	$9.04B	Sell	95,551,631 -653,053	-0.7%	-$61.9M	0.39%	40
2018 Q2	$8.91B	Sell	96,204,684 -3,840,394	-4%	-$375M	0.41%	37
2018 Q1	$9.47B	Sell	100,045,078 -1,277,123	-1%	-$140M	0.45%	33
2017 Q4	$9.8B	Buy	101,322,201 +2,714,857	+3%	+$256M	0.47%	34
2017 Q3	$8.76B	Buy	98,607,344 +4,532,382	+5%	+$345M	0.44%	37
2017 Q2	$6.82B	Buy	94,074,962 +1,864,418	+2%	+$125M	0.36%	46
2017 Q1	$6.01B	Buy	92,210,544 +88,237,132	+2,221%	+$5.55B	0.33%	48
2016 Q4	$249M	Sell	3,973,412 -210,973	-5%	-$12.9M	0.35%	48
2016 Q3	$264M	Sell	4,184,385 -304,775	-7%	-$19.7M	0.38%	51
2016 Q2	$278M	Buy	4,489,160 +563,107	+14%	+$34.3M	0.42%	47
2016 Q1	$224M	Sell	3,926,053 -1,485,506	-27%	-$82.8M	0.36%	57
2015 Q4	$321M	Sell	5,411,559 -360,562	-6%	-$20.8M	0.47%	44
2015 Q3	$314M	Sell	5,772,121 -157,513	-3%	-$10.3M	0.49%	41
2015 Q2	$398M	Sell	5,929,634 -884,768	-13%	-$57.8M	0.59%	31
2015 Q1	$399M	Buy	6,814,402 +873,003	+15%	+$52.7M	0.55%	34
2014 Q4	$389M	Buy	5,941,399 +399,111	+7%	+$25.2M	0.56%	35
2014 Q3	$320M	Sell	5,542,288 -768,934	-12%	-$42.7M	0.47%	45
2014 Q2	$356M	Buy	6,311,222 +5,820	+0.1%	+$305K	0.53%	33
2014 Q1	$324M	Sell	6,305,402 -93,759	-1%	-$4.74M	0.52%	37
2013 Q4	$338M	Buy	6,399,161 +615,123	+11%	+$30.2M	0.55%	36
2013 Q3	$259M	Sell	5,784,038 -255,619	-4%	-$11.3M	0.49%	41
2013 Q2	$250M	Buy	+6,039,657	New	+$264M	0.49%	43

Other funds holding ABBV

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock's ABBV Position: Q1 2026 in Review

BlackRock reduced its AbbVie (ABBV) stake by 0.32% in Q1 2026, selling an estimated $106M and leaving 150,698,125 shares worth $32.8B. The position accounts for 0.57% of the portfolio, ranked #22.

BlackRock first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.5B in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

BlackRock held 150,698,125 shares of AbbVie worth $32.8B as of Q1 2026.
BlackRock sold 476,418 AbbVie shares in Q1 2026, an estimated $106M.
AbbVie made up 0.57% of BlackRock's portfolio in Q1 2026, its #22 holding.
BlackRock first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
BlackRock's AbbVie position peaked at $34.5B in Q4 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.